Nurix says Sanofi discontinues autoimmune disease drug program

What happened

Nurix said Sanofi will stop developing SAR448272, an experimental oral treatment for autoimmune and inflammatory diseases, after ending an early-stage trial. Nurix said it no longer expects related milestone payments or royalties, while other drug candidates in its Sanofi collaboration remain eligible for such payments.

Confirmed

Global impact / market context

The decision removes a possible future source of revenue for Nurix: development and sales-related payments and royalties tied to this drug. That may reduce investors’ expectations for the collaboration’s value, although Nurix says payments from other candidates remain possible.

Analyst inference

Sanofi’s decision removes potential future milestone payments and royalties for this Nurix program, while Nurix says payments from other Sanofi candidates remain possible. The reported cash balance and expected operating runway provide a separate funding context, but the article does not establish how investors will value that outlook.

Analyst inference

What to watch

1. Watch for further details on Sanofi’s decision or any change to the collaboration, since the article says other candidates can still generate milestone payments and royalties. Analyst inference
2. Track Nurix’s financial updates for evidence that the loss of this program changes its expected cash runway, which is how long available funds can support operations. Analyst inference
3. Nurix said it remains eligible for milestone payments and royalties from other drug candidates being developed under its Sanofi collaboration agreement. Confirmed

Evidence

• Original source link unavailable